JATT II Acquisition agrees to merge with Talawar Therapeutics in deal backed by USD 225 million PIPE

JATT II Acquisition Corp.

JATT II Acquisition Corp.

JATT

0.00
  • Talawar Therapeutics agreed to combine with SPAC JATT II Acquisition Corp., creating a Nasdaq-listed biotech expected to trade as TLWR.
  • Closing is targeted for 2H 2026, subject to shareholder and regulatory clearances.
  • The deal is expected to deliver USD 285 million in gross proceeds before transaction costs, assuming no redemptions.
  • Funding includes USD 60 million from JATT II’s trust account and a USD 225 million PIPE priced at USD 10 per share.
  • Cash at close is expected to fund Talawar’s lead program TALA-125 through a Phase 2b readout in 2H 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JATT II Acquisition Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH93353) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.